Ratings AbbVie Inc. London S.E.

Equities

0QCV

US00287Y1091

Delayed London S.E. Other stock markets 03:04:19 2024-04-25 am EDT			5-day change	1st Jan Change
167.9 ^USD	-0.61%		+1.82%	+8.58%

12:11pm	Scholz promises support for pharma sector in Germany as Merck invests	RE
Apr. 23	US CDC warns of harmful reactions to fake Botox injections	RE

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Sales forecast by analysts have been recently revised upwards.
Over the past four months, analysts' average price target has been revised upwards significantly.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The group shows a rather high level of debt in proportion to its EBITDA.
With an expected P/E ratio at 30.29 and 24.86 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last few months, analysts have been revising downwards their earnings forecast.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ABBVIE INC.	+8.58%	297B	-
ELI LILLY AND COMPANY	+25.61%	660B	C+
NOVO NORDISK A/S	+22.83%	562B	B
JOHNSON & JOHNSON	-5.24%	358B	C+
MERCK & CO., INC.	+16.49%	322B	B-
ASTRAZENECA PLC	+12.53%	219B	B+
ROCHE HOLDING AG	-9.61%	196B	A+
NOVARTIS AG	+6.48%	199B	B-
PFIZER, INC.	-8.75%	149B	C+
AMGEN INC.	-5.21%	146B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes